This content is machine translated From Risk Identification to Anti-Inflammatory Intervention Inflammation as a Treatment Goal in Its Own Right For decades, cardiovascular prevention was essentially a story about cholesterol. Yet a significant proportion of patients experience adverse events despite optimally controlled lipid levels—a reflection of a residual risk that...… CME-Test
View Post 11 min This content is machine translated Cardiometabolism Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943)...…
View Post 14 min This content is machine translated Focus Update 2026 Echocardiography in Cardio-Oncology With advances in oncology, more and more people are surviving cancer—and this has brought the long-term cardiovascular effects of treatment into focus. Cancer therapy-related cardiac dysfunction (CTRCD ) has become...…
View Post 5 min This content is machine translated Psoriasis in the Age of Precision Medicine Systemic Therapy for Patients with Comorbidities: What Is the Best Choice? Psoriasis is a chronic inflammatory systemic disease often associated with comorbidities, a fact that must be taken into account during treatment. Particular attention should be paid to psoriatic arthritis (PsA),...…
View Post 13 min This content is machine translated The AMALFI study and the limits of digital screening for atrial fibrillation Remote monitoring for atrial fibrillation: lots of detection, little stroke prevention? Atrial fibrillation (AF) is often asymptomatic, increases stroke risk and can be treated with anticoagulation – so the logic of screening seems compelling. New patches, loop recorders and smartwatches promise...…
View Post 12 min This content is machine translated Why the Finerenon Boom Is Giving Hyperkalemia Treatment New Relevance Potassium binders as enablers of RAASi optimization Renin-angiotensin-aldosterone system (RAAS) inhibitors—including mineralocorticoid receptor antagonists (MRAs)—are among the most effective tools in cardiorenal medicine. However, their benefits are often undermined in everyday clinical practice because fear of hyperkalemia...…
View Post 12 min This content is machine translated SURPASS-CVOT Tirzepatide versus Dulaglutide in T2D with ASCVD GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that...…
View Post 6 min This content is machine translated Secondary prevention after ACS: individually optimized lipid management Trend towards early combination therapy and new strategies for lowering Lp(a) Secondary prevention after an acute coronary syndrome (ACS) is crucial for improving quality of life and reducing morbidity and mortality rates. Elevated blood lipid levels such as LDL cholesterol and...…
View Post 13 min This content is machine translated What the latest studies on the entire EF spectrum mean for clinical practice Heart Failure – The 2026 Evidence Update Since the release of the 2021 ESC guidelines and the 2022 AHA/ACC/HFSA guidelines, research on heart failure has reached a remarkable level of intensity. Nonsteroidal mineralocorticoid receptor antagonists and incretin-based...…
View Post 2 min This content is machine translated Wearables: screening via smartwatch? New study on atrial fibrillation in high-risk patients Wearable devices with photoplethysmography and ECG capabilities offer a non-invasive and scalable method of monitoring heart rate. A recently published randomized controlled trial provided evidence that six months of screening...…
View Post 12 min This content is machine translated Global Recommendation, Swissmedic Approval, and SL Limitation WHO Guidelines on GLP-1 for Obesity With the guideline published on December 1, 2025, the World Health Organization has, for the first time, issued a globally applicable recommendation on the pharmacological management of obesity in adults....…
